Pharma Mar SA (PHMMF)
87.58
0.00 (0.00%)
USD |
OTCM |
Aug 21, 16:00
Pharma Mar Net Income (Quarterly) : -1.130M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.130M |
| March 31, 2026 | 1.794M |
| December 31, 2025 | 69.45M |
| September 30, 2025 | -4.791M |
| June 30, 2025 | 26.49M |
| March 31, 2025 | -4.156M |
| December 31, 2024 | 19.93M |
| September 30, 2024 | 4.289M |
| June 30, 2024 | 1.332M |
| March 31, 2024 | 2.496M |
| December 31, 2023 | -7.333M |
| September 30, 2023 | 1.655M |
| June 30, 2023 | 5.468M |
| March 31, 2023 | 1.514M |
| December 31, 2022 | 1.417M |
| June 30, 2022 | 13.78M |
| March 31, 2022 | 24.65M |
| December 31, 2021 | 40.81M |
| September 30, 2021 | 13.55M |
| June 30, 2021 | 22.94M |
| March 31, 2021 | 29.13M |
| December 31, 2020 | 7.355M |
| September 30, 2020 | 20.22M |
| June 30, 2020 | 47.60M |
| March 31, 2020 | 77.74M |
| Date | Value |
|---|---|
| December 31, 2019 | 17.26M |
| September 30, 2019 | -6.291M |
| June 30, 2019 | -9.748M |
| March 31, 2019 | -11.85M |
| December 31, 2018 | -3.541M |
| September 30, 2018 | -16.90M |
| June 30, 2018 | 3.620M |
| March 31, 2018 | -3.080M |
| December 31, 2017 | -14.24M |
| September 30, 2017 | -8.255M |
| June 30, 2017 | -5.494M |
| March 31, 2017 | -2.627M |
| December 31, 2016 | -8.081M |
| September 30, 2016 | -3.814M |
| June 30, 2016 | -6.831M |
| March 31, 2016 | -7.873M |
| December 31, 2015 | -1.189M |
| September 30, 2015 | 4.865M |
| June 30, 2015 | -3.524M |
| March 31, 2015 | 7.364M |
| December 31, 2014 | -5.526M |
| September 30, 2014 | 0.9552M |
| June 30, 2014 | -0.1454M |
| March 31, 2014 | 23.27M |
| December 31, 2013 | -3.543M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Oryzon Genomics SA | -0.1678M |
| Grifols SA | 212.78M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alkermes Plc | 0.501M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 57.68M |
| Total Expenses (Quarterly) | 58.81M |
| EPS Diluted (Quarterly) | -0.0652 |
| Enterprise Value | 1.378B |
| Gross Profit Margin (Quarterly) | 86.21% |
| Profit Margin (Quarterly) | -1.96% |
| Earnings Yield | 4.27% |
| Operating Earnings Yield | 2.42% |
| Normalized Earnings Yield | 4.272 |